Does Humana Cover Vyleesi (Bremelanotide)?

What Is Vyleesi and Why Does Coverage Get Complicated?

Vyleesi (bremelanotide) is a melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized HSDD in premenopausal women [1]. It is injected subcutaneously 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per eight days on average. The drug is not a hormone; it acts centrally on MC1R and MC4R receptors to modulate sexual desire pathways [2].

Coverage complexity comes from two overlapping problems. First, HSDD is a legitimate medical diagnosis under DSM-5, yet some insurers still classify sexual-dysfunction drugs as lifestyle medications and apply exclusions accordingly. Second, bremelanotide's mechanism temporarily raises blood pressure, which made the FDA add a warning against use in patients with cardiovascular disease [1]. That warning gives utilization-management teams a ready-made medical-necessity argument for denial.

The key RECONNECT trials (two identical randomized controlled trials, N=1,247 total) published in Obstetrics and Gynecology in 2019 showed that bremelanotide produced a statistically significant improvement on the Female Sexual Function Index desire domain compared with placebo (P<0.001), with 25% of treated women reporting meaningful benefit versus 17% on placebo [3]. Those trials are the core clinical evidence your prescriber will reference in any prior-authorization submission.

Because HSDD is classified as a mental health condition under DSM-5, the Mental Health Parity and Addiction Equity Act of 2008 may require commercial plans that cover psychiatric drugs to apply no stricter utilization-management criteria to bremelanotide than they would to a comparable non-psychiatric drug. That legal angle is worth raising explicitly in an appeal letter [4].

How Humana's Formulary Works for Vyleesi

Humana operates dozens of distinct plan types, including HMO, PPO, and PFFS commercial products and multiple Medicare Advantage Part D formularies. Vyleesi does not appear on Humana's national standard formulary as a covered specialty tier drug in most plan years. That means each regional or employer-sponsored plan makes its own determination [5].

Formulary tiers matter because they set both the copay structure and the prior-authorization rules. When Vyleesi appears on a Humana commercial formulary at all, it typically lands on Tier 4 or Tier 5 (specialty or non-preferred specialty), with list-price-adjacent cost-sharing before the out-of-pocket maximum is reached. The FDA-approved label provides the clinical framework that formulary committees use when deciding placement [1].

If your specific Humana plan year's formulary document does not list bremelanotide, the drug is "non-formulary." Non-formulary drugs are not automatically uncoverable. You can request a formulary exception, which is a separate process from a standard PA. A formulary exception requires documentation that the covered alternatives are medically contraindicated or clinically inappropriate for you specifically [6].

Checking your exact formulary: log into MyHumana, select "Drug Cost and Coverage," and search for bremelanotide or Vyleesi. The result will show either a tier, a "not covered" flag, or a "restrictions apply" flag with a link to the PA criteria document.

Humana Prior-Authorization Criteria for Vyleesi

Prior authorization for bremelanotide on Humana commercial plans generally requires all of the following elements, based on standard industry utilization-management criteria and Humana's published clinical coverage policies [5]:

The prescriber must confirm a diagnosis of acquired, generalized HSDD consistent with DSM-5 criteria. The diagnosis must be in a premenopausal woman, matching the FDA-approved population exactly [1]. Documentation of a structured clinical assessment, such as the Female Sexual Distress Scale-Revised (FSDS-R) score of 11 or higher, strengthens the submission substantially [3].

Humana typically requires exclusion of reversible causes before approving bremelanotide. Reversible causes include relationship distress, untreated depression, thyroid dysfunction, hyperprolactinemia, and medication-induced desire loss (for example, from SSRIs or hormonal contraceptives). Lab work confirming normal TSH, prolactin, and free testosterone is a standard attachment [7].

Some Humana plans apply step therapy, requiring a documented trial of flibanserin (Addyi) 100 mg at bedtime for at least 8 weeks before approving bremelanotide. If the patient experienced intolerance or inadequate response to flibanserin, the PA packet should include a specific note from the prescriber describing the adverse effects or lack of efficacy [8].

Cardiovascular screening is mandatory. Because bremelanotide transiently raises blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic, with some patients showing increases of 27 mmHg systolic, Humana's medical directors will not approve the drug for patients with uncontrolled hypertension or established cardiovascular disease [1]. A recent blood pressure reading and, ideally, a 12-lead ECG are helpful attachments.

The complete PA packet should contain: the signed PA request form, ICD-10 code F52.0 (hypoactive sexual desire dysfunction), the FSDS-R score with date, lab results (TSH, prolactin, free testosterone), blood pressure documentation, the prescriber's narrative letter addressing each criterion, and (if applicable) documentation of prior flibanserin failure.

Humana Medicare Advantage and Vyleesi

Medicare Advantage plans follow Part D formulary rules set by CMS. CMS explicitly excludes from Part D coverage any drug "used for cosmetic purposes or hair growth" and any drug used for "sexual or erectile dysfunction, unless such drug were used to treat a condition, other than sexual or erectile dysfunction, for which the drug has been approved" [9].

Bremelanotide has one FDA-approved indication: HSDD. There is no off-label cardiovascular or other use recognized by CMS compendia that would create a coverage pathway. The practical result is that virtually every Humana MA plan excludes Vyleesi. The manufacturer savings card cannot be used with Medicare, Medicaid, or any other federal health benefit program [10].

The one narrow exception worth exploring: if a patient is enrolled in a Low Income Subsidy (LIS) or Extra Help program, their formulary is slightly different, but the CMS categorical exclusion still applies to bremelanotide. There is no current pathway to Part D coverage for this drug under any MA plan.

How to Appeal a Humana Denial of Vyleesi

Humana must follow the appeals process outlined under the Affordable Care Act for commercial plans and under CMS regulations for MA plans. Timelines and steps differ between the two [11].

For commercial plan denials, the process moves through two internal levels. Level 1 is an internal reconsideration, which Humana must complete within 30 days for non-urgent requests or 72 hours for urgent/expedited requests. Level 2 is an external review conducted by an independent review organization (IRO) accredited under state law. If the IRO overturns the denial, Humana must cover the drug [12].

For Medicare Advantage denials, the five-level process is: (1) Redetermination by Humana, within 7 days standard or 72 hours expedited; (2) Reconsideration by the Qualified Independent Contractor (QIC), currently Maximus Federal Services; (3) ALJ hearing at the Office of Medicare Hearings and Appeals; (4) Medicare Appeals Council review; (5) Federal district court, when the amount in controversy exceeds $1,870 (2024 threshold) [13].

The MA appeal for bremelanotide faces a structural obstacle: the CMS categorical exclusion is not a medical-necessity denial, it is a coverage exclusion. Coverage exclusions cannot be overturned on medical grounds alone. The appeal argument must instead challenge whether CMS's categorical exclusion applies to this specific use, which is a legal argument requiring documentation that bremelanotide is treating a DSM-5 diagnosed psychiatric condition rather than a lifestyle concern [4].

A strong appeal letter for a commercial denial should include:

The specific Humana coverage policy number being challenged. A statement that HSDD is a DSM-5 Axis I disorder and that bremelanotide is the only FDA-approved as-needed pharmacotherapy for this condition [2]. Reference to the two RECONNECT RCTs showing statistically significant efficacy (P<0.001) in 1,247 women [3]. A Mental Health Parity argument citing 29 CFR 2590.712 if the denial applied stricter criteria than those used for a comparable non-psychiatric drug [4]. Board-certified OB/GYN or sexual-medicine specialist support letter.

Out-of-Pocket and Savings Card Options

The list price for Vyleesi is approximately $1,200 per month, which aligns with AMAG Pharmaceuticals' (now Palatin Technologies' licensee Cosette Pharmaceuticals) launch pricing [10]. Without insurance or with a non-formulary denial, most patients pay close to list price unless they use the manufacturer savings program.

The Vyleesi savings card, available at the manufacturer's website, can reduce out-of-pocket cost significantly for commercially insured patients who qualify. Eligibility requires that the patient is not enrolled in Medicare, Medicaid, TRICARE, or any other federal or state-funded health benefit program [10]. For patients with commercial insurance that covers Vyleesi after PA, the savings card may bring the copay to as low as $0 per month depending on plan terms.

Patients without any insurance coverage have two realistic options: the savings card at list price reduction, or compounded bremelanotide from a 503A compounding pharmacy. Compounded versions are not FDA-approved and carry quality and sterility risks. The FDA has not placed bremelanotide on the drug shortage list, so compounding is not automatically permissible under federal law [1]. A prescribing clinician should document the patient's informed consent and clinical rationale carefully if a compounded route is chosen.

What the Evidence Says About Efficacy (and What It Doesn't)

The two RECONNECT phase-3 trials enrolled 1,247 premenopausal women with DSM-5 HSDD across 96 sites and ran for 24 weeks. The primary endpoints were change from baseline on the FSDS-R and change in the number of satisfying sexual events (SSEs). Bremelanotide produced a 0.7-point mean decrease on the FSDS-R distress score versus a 0.4-point decrease for placebo (P<0.001), and a mean increase of 0.5 SSEs per month versus 0.2 for placebo [3].

Those numbers are modest in absolute terms. The FDA acknowledged this and noted that about 25% of treated women experienced meaningful benefit. The agency approved the drug because HSDD causes significant distress, no other as-needed option existed, and the risk profile was acceptable for premenopausal women without cardiovascular disease [1].

Nausea was the most common adverse effect, reported in 40% of bremelanotide users versus 1% of placebo in the RECONNECT trials, with most episodes resolving within 2 hours [3]. Flushing occurred in 20% of patients. Transient blood pressure elevation, the most clinically significant concern, occurred in virtually all patients by a mean of 2 mmHg systolic but resolved within 12 hours in the majority of cases [1].

No published trial has evaluated bremelanotide for weight loss in humans at the doses used for HSDD. Higher-dose melanotan analogs have been studied for obesity, but the 1.75 mg subcutaneous dose in Vyleesi is not associated with clinically meaningful weight change in RECONNECT data [3]. Humana's coverage of Vyleesi is therefore governed entirely by HSDD criteria, not weight-loss exclusions. CMS applies weight-loss drug exclusions only if a drug is approved or used for that purpose [9].

Prescriber and Plan-Navigation Checklist

Assembling a clean PA packet dramatically improves approval odds. The following steps reflect standard utilization-management expectations across major commercial payers including Humana [5].

Confirm the DSM-5 FSDS-R score at baseline and attach the scored form to the PA request. The score must be 11 or higher to document clinically significant distress [3]. Run a full hormonal workup: TSH, prolactin, free testosterone, LH, FSH, and estradiol. Abnormal results require treatment before bremelanotide can be justified as the appropriate next step [7].

Document blood pressure at the visit. Any reading above 130/80 mmHg should be addressed and a follow-up reading obtained before submission [1]. If the patient previously tried flibanserin and discontinued due to adverse effects or inadequate response, attach a specific narrative. Vague statements like "patient did not respond" are easier to deny than "patient completed 8 weeks of flibanserin 100 mg nightly and discontinued at week 6 due to intolerable dizziness, documented in the chart on [date]" [8].

The prescriber's specialty matters. PA requests from board-certified gynecologists, reproductive endocrinologists, or certified menopause practitioners (NAMS Certified Menopause Practitioner credential) carry more weight with Humana's medical directors than requests from non-specialist providers [6].

Submit the PA request at least 2 weeks before the patient needs the medication. Urgent or expedited requests require documentation of clinical urgency, which is difficult to establish for HSDD; standard review timelines apply in nearly every case.

If denied, request the denial letter in writing and compare the stated reason against Humana's published clinical coverage policy for bremelanotide. Any mismatch between the denial rationale and the written policy criteria is grounds for a procedural appeal, which carries a higher overturn rate than a purely clinical appeal [11].